Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Nutritional Status Evaluation in Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder - Site Manado (GROW)

11 novembre 2026 aggiornato da: PT Equilab International

Evaluation of the Nutritional Status of Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder: An Open-Label, Single-Arm, Prospective Study (GROW Study)

The goal of this clinical trial is to learn whether daily use of Investigational Product (IP), an energy-dense milk powder, improves growth in Indonesian children aged 24 to 48 months who are underweight. The main question it aims to answer is whether Investigational Product (IP) improves children's weight relative to their age after 6 months of use.

Researchers will also assess changes in height, weight relative to height, body mass index, head size, growth rate, digestive comfort, and safety.

Participants will:

  • Complete a 7-day feeding trial to check whether they can tolerate and accept the study product.
  • Drink two servings of Investigational Product (IP) each day for 6 months.
  • Visit the study site regularly for growth measurements and other study assessments.
  • Record daily product intake and digestive symptoms, and report any health problems during the study.

The study will enroll at least 74 children combined from 2 sites (Manado, 37 children; Makassar, 37 children). All participants will receive Investigational Product (IP). There is no placebo or comparison group.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This study evaluates the effect of daily supplementation with Investigational Product (IP), an energy-dense milk powder providing 0.89 kcal/mL, on the nutritional status and growth of Indonesian children aged 24 to 48 months who are underweight.

The study uses an open-label, single-arm, prospective interventional design. All enrolled participants receive the same study product, and there is no randomization, blinding, placebo, or non-intervention control group. Changes during the intervention are evaluated by comparing each participant's measurements with their baseline values. The study design was selected because the study population consists of children with moderate underweight, and withholding nutritional support through a placebo or non-intervention group was considered inappropriate in the study protocol.

Before enrollment, potentially eligible children complete a 7-day feeding trial. During this period, caregivers prepare and provide the study product according to standardized instructions and record daily intake, leftovers, and gastrointestinal symptoms. The feeding trial is used to assess initial product acceptance and gastrointestinal tolerance. Children who successfully complete the feeding trial and remain eligible proceed to the baseline assessment and the 6-month intervention period.

During the intervention period, participants consume two servings of Investigational Product (IP) each day for approximately 6 months. The study product is dispensed regularly, and caregivers record daily product consumption and gastrointestinal symptoms in study diaries. Study staff review product use and returned product packaging to assess adherence. Safety monitoring for adverse events and serious adverse events continues throughout the study.

Growth and nutritional status are assessed during scheduled study visits using anthropometric measurements. Additional assessments are used to characterize gastrointestinal tolerance, body composition and body measurements, child behavioral and emotional functioning, dietary patterns, product acceptability, caregiver satisfaction, and safety.

The study plans to enroll at least 74 children, with at least 37 participants recruited at each of the two study sites in Manado and Makassar. An interim analysis is planned around Month 3 to review data completeness, protocol adherence, participant safety, and overall study progress. The interim analysis is descriptive and exploratory and is not intended for formal efficacy hypothesis testing.

The study is intended to provide information on the potential effect of 6 months of milk product supplementation on growth and nutritional status, while also describing gastrointestinal tolerance, safety, product acceptability, and other related nutritional and developmental measures in this population.

Tipo di studio

Interventistico

Iscrizione (Stimato)

37

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • North Sulawesi
      • Manado, North Sulawesi, Indonesia, 95239
        • Reclutamento
        • Puskesmas Tuminting
        • Contatto:
        • Investigatore principale:
          • Bobby Pambudi, Sp.A,Subsp. NPM(K)
        • Sub-investigatore:
          • Lydia Wangke, Sp.A (K)
        • Sub-investigatore:
          • Ronald Rompies, SpA, Subsp. NPM (K)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 2 anni a 4 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Children aged 24 to 48 months at the time of enrollment.
  • Classified as underweight according to the World Health Organization Growth Standards 2006, with a Weight-for-Age Z-score below -2.
  • Willing to participate and consume the study product, a milk powder providing 0.89 kcal/mL, during the 7-day feeding trial and 6-month intervention period.
  • Parent or legal guardian has provided signed informed consent before participation
  • No plan to relocate or move residence within the next 8 months during the study period
  • Able and willing to comply with study procedures, including scheduled visits, dietary recalls, and product consumption recording
  • Completed the 7-day feeding trial and demonstrated tolerance of the study product without aversion, intolerance, or allergic reaction, as confirmed by the study physician
  • Parent or primary caregiver has adequate literacy to understand study instructions, with a minimum education level of completed senior high school.

Exclusion Criteria:

  • History of preterm birth, defined as gestational age below 37 weeks
  • Birth weight below 2,500 g or above 4,000 g
  • Weight-for-Height Z-score below -2 standard deviations, indicating moderate acute malnutrition
  • Height-for-Age Z-score below -2, indicating stunting
  • Presence of historic of chronic or infectious diseases, including tuberculosis, congenital heart disease, or other acute or chronic illness that may affect nutritional intake or growth
  • Diagnosed cow's milk protein allergy or lactose intolerance by a healthcare professional
  • Currently participating in another clinical or nutrition intervention study
  • Presence of signs suggestive of anemia, identified through non-invasive physical examination by a pediatric clinician
  • Inability to tolerate or complete the 7-day feeding trial, including moderate to severe gastrotinestinal symptoms related to the study product or inability to complete 7 full days of product consumption
  • Any condition that, in the investigator's judgement, makes the child unsuitable for the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: GROPLUS Milk Powder

Participants will receive GROPLUS milk powder with an energy density of 0.89 kcal/mL for 6 months. Participants will consume two servings of the study product each day according to standardized preparation and administration instructions. Study staff will monitor product use, gastrointestinal tolerance, adherence, and safety throughout the intervention period.

GROPLUS is an energy-dense milk powder providing 0.89 kcal/mL when prepared according to the study instructions. Participants will consume two servings per day for approximately 6 months. The product will be prepared and administered according to standardized study instructions, with product use and compliance monitored throughout the intervention period.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Weight-for-Age Z-score from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in Weight-for-Age Z-score (WAZ), calculated using the 2006 World Health Organization Child Growth Standards. Weight and age measurements collected at baseline and Month 6 will be used to determine WAZ. The change will be calculated as the difference between the Month 6 and baseline WAZ values and evaluated against a predefined minimal clinically important difference of 0.20 Z-score.

From baseline (Month 0) to Month 6

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Height Gain Velocity from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Rate of height gain expressed in millimeters per month (mm/month), calculated from serial height measurements collected during the study. Height velocity will be assessed between baseline and Month 6.

From baseline (Month 0) to Month 6
Incidence and Frequency of Adverse Events and Common Infectious Illnesses
Lasso di tempo: From baseline (Month 0) through Month 6

The incidence and frequency of adverse events during the intervention period, including common infectious illnesses such as upper respiratory tract infection, diarrhea, and fever. Adverse events will be monitored and documented throughout the intervention period.

From baseline (Month 0) through Month 6
Change in Height-for-Age Z-score from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in Height-for-Age Z-score (HAZ), calculated using the 2006 World Health Organization Child Growth Standards. Height measurements collected at baseline and Month 6 will be used to assess change in linear growth.

From baseline (Month 0) to Month 6
Change in Weight-for-Height Z-score from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in Weight-for-Height Z-score (WHZ), calculated using the 2006 World Health Organization Child Growth Standards. Weight and height measurements collected at baseline and Month 6 will be used to assess proportional growth and weight relative to height.

From baseline (Month 0) to Month 6
Change in Body Mass Index-for-Age Z-score from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in Body Mass Index-for-Age Z-score (BAZ), calculated from body mass index measurements standardized using World Health Organization reference values. The change will be assessed between baseline and Month 6.

From baseline (Month 0) to Month 6
Change in Head Circumference-for-Age Z-score from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in Head Circumference-for-Age Z-score (HCZ), calculated using the 2006 World Health Organization Child Growth Standards. Head circumference measurements collected at baseline and Month 6 will be used to assess change.

From baseline (Month 0) to Month 6
Weight Gain Velocity from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Rate of weight gain expressed in grams per month (g/month), calculated from serial body weight measurements collected during the study. Weight velocity will be assessed between baseline and Month 6

From baseline (Month 0) to Month 6
Change in Gastrointestinal Tolerance from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in gastrointestinal tolerance assessed using the Toddler Gut Comfort Questionnaire (TGCQ). The assessment includes total and domain scores reflecting gastrointestinal comfort. Scores will be compared between baseline and Month 6.

From baseline (Month 0) to Month 6
Change in Mid-Upper Arm Circumference from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in mid-upper arm circumference measured in centimeters (cm), based on measurements collected at baseline and Month 6.

From baseline (Month 0) to Month 6
Change in Waist Circumference from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in waist circumference measured in centimeters (cm), based on measurements collected at baseline and Month 6.

From baseline (Month 0) to Month 6
Change in Hip Circumference from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in hip circumference measured in centimeters (cm), based on measurements collected at baseline and Month 6

From baseline (Month 0) to Month 6
Change in Head Circumference from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in head circumference measured in centimeters (cm), based on measurements collected at baseline and Month 6.

From baseline (Month 0) to Month 6
Calf Circumference from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in calf circumference measured in centimeters (cm), based on measurements collected at baseline and Month 6.

From baseline (Month 0) to Month 6
Change in Triceps Skinfold Thickness from Baseline to Month 6
Lasso di tempo: At baseline (Month 0), Month 3, and Month 6

Change in triceps skinfold thickness measured in millimeters (mm), based on measurements collected at baseline and Month 6.

At baseline (Month 0), Month 3, and Month 6
Change in Biceps Skinfold Thickness from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in biceps skinfold thickness measured in millimeters (mm), based on measurements collected at baseline and Month 6.

From baseline (Month 0) to Month 6
Subscapular Skinfold Thickness from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in subscapular skinfold thickness measured in millimeters (mm), based on measurements collected at baseline and Month 6.

From baseline (Month 0) to Month 6
Change in Abdominal Skinfold Thickness from Baseline to Month 6
Lasso di tempo: From baseline (Month 0) to Month 6

Change in abdominal skinfold thickness measured in millimeters (mm), based on measurements collected at baseline and Month 6.

From baseline (Month 0) to Month 6
Change in Knee Height from Baseline to Month 6
Lasso di tempo: At baseline (Month 0), Month 3, and Month 6

Change in knee height, measured in centimeters (cm), assessed using Anthropometer Caliper. Measurements will be collected at baseline, Month 3, and Month 6 to assess changes in knee height over the study period.

At baseline (Month 0), Month 3, and Month 6
Change in Arm Span from Baseline to Month 6
Lasso di tempo: At baseline (Month 0), Month 3, and Month 6

Change in arm span measured at baseline, Month 3, and Month 6. Measurements will be compared across the specified assessment time points.

At baseline (Month 0), Month 3, and Month 6

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Child Behavioral and Emotional Functioning
Lasso di tempo: At baseline (Month 0), Month 3, and Month 6

Change in child behavioral and emotional functioning assessed using the Child Behavior Checklist (CBCL). Assessments will be conducted at baseline, Month 3, and Month 6, including internalizing, externalizing, and total problem scores.

At baseline (Month 0), Month 3, and Month 6
Baseline Dietary Patterns and Macronutrient Intake
Lasso di tempo: At baseline (Month 0)

Baseline habitual dietary patterns and macronutrient intake assessed using a validated Food Frequency Questionnaire (FFQ) before the 6-month supplementation period.

At baseline (Month 0)
Caregiver-Reported Child Liking of Product Appearance
Lasso di tempo: Every 2 weeks from baseline through Month 6

Child's liking of the study product's appearance, as reported by the parent or caregiver using the study-specific Child Product Liking Questionnaire with a pictorial response scale. Responses are categorized as dislike (0), neutral (1), or like (2), with a possible score range of 0 to 2. Higher scores indicate greater liking.

Every 2 weeks from baseline through Month 6
Caregiver-Reported Child Liking of Product Taste
Lasso di tempo: Every 2 weeks from baseline through Month 6

Child's liking of the study product's taste, as reported by the parent or caregiver using the study-specific Child Product Liking Questionnaire with a pictorial response scale. Responses are categorized as dislike (0), neutral (1), or like (2), with a possible score range of 0 to 2. Higher scores indicate greater liking.

Every 2 weeks from baseline through Month 6
Caregiver-Reported Child Liking of Product Texture
Lasso di tempo: Every 2 weeks from baseline through Month 6

Child's liking of the study product's texture, as reported by the parent or caregiver using the study-specific Child Product Liking Questionnaire with a pictorial response scale. Responses are categorized as dislike (0), neutral (1), or like (2), with a possible score range of 0 to 2. Higher scores indicate greater liking

Every 2 weeks from baseline through Month 6
Parent or Caregiver Satisfaction with Product Use and Feeding Experience
Lasso di tempo: Every 2 weeks from baseline through Month 6

Parent or caregiver satisfaction with the nutritional quality of the study product, assessed using the study-specific Parent/Caregiver Satisfaction Questionnaire. Responses are categorized as yes, neutral, no, or unwilling to respond. Results will be reported as the number and percentage of participants in each response category.

Every 2 weeks from baseline through Month 6

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 marzo 2025

Completamento primario (Stimato)

31 marzo 2027

Completamento dello studio (Stimato)

31 maggio 2027

Date di iscrizione allo studio

Primo inviato

8 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CR.202/EQL/2025_MAN

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

There is no plan to share individual participant data (IPD) with other researchers. The study data will be maintained by the Sponsor and study team and will be used for the purposes described in the study protocol. Participant confidentiality and data privacy will be maintained.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .